title: Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
abstract: Tuberculosis (TB) is a reemerging disease. The only available vaccine, Mycobacterium bovis BCG, is delivered intradermally and confers highly variable efficacy against pulmonary disease. There is an urgent need for improved vaccination strategies. Murine studies suggest that immunizations delivered directly to the respiratory mucosa might be a more effective route of vaccination. This study compared the immunogenicity of a leading candidate tuberculosis (TB) vaccine, modified vaccinia virus Ankara expressing antigen 85A (MVA85A), in rhesus macaques, delivered either as an aerosol or as an intradermal boost immunization 12 weeks after an intradermal BCG prime vaccine. Aerosol vaccination was well tolerated. MVA85A delivered by aerosol or by intradermal injection induced antigen-specific immune responses in the periphery and the lung, with a trend toward the highest response when the compartment and route of delivery were matched. The ability of poxvirus-vectored vaccines delivered by the systemic route to induce responses in the mucosal immune compartment in macaques is in contrast to the independent compartmentalization of mucosal and systemic immune systems described in mice. Unlike intradermal vaccination, aerosol vaccination did not induce a detectable serum anti-vector antibody response. The delivery of vaccines to the lungs might provide an immunization strategy that limits the induction of systemic anti-vector immunity, which would be extremely useful in the development of improved vaccine strategies. This is the first study to show a recombinant MVA-vectored vaccine to be highly immunogenic when delivered by the aerosol route to nonhuman primates. These results provide important safety and proof-of-concept data for further evaluation of this route of immunization for use in human clinical trials.
authors: Health Protection Agency, Microbiological Services Division, Porton Down, Salisbury, United Kingdom.
authors: A D
authors: AD
authors: White
authors: L
authors: L
authors: Sibley
authors: M J
authors: MJ
authors: Dennis
authors: K
authors: K
authors: Gooch
authors: G
authors: G
authors: Betts
authors: N
authors: N
authors: Edwards
authors: A
authors: A
authors: Reyes-Sandoval
authors: M W
authors: MW
authors: Carroll
authors: A
authors: A
authors: Williams
authors: P D
authors: PD
authors: Marsh
authors: H
authors: H
authors: McShane
authors: S A
authors: SA
authors: Sharpe
mesh_terms: D000280:Administration, Inhalation; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018928:Immunity, Mucosal / Q000276:immunology; D007117:Immunization, Secondary; D008251:Macaca; D009163:Mycobacterium bovis / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology* / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; C549320:MVA 85A; D032581:Tuberculosis Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic